CombinatoRx to Host 2006 Research & Development Day
Posted on: Monday, 17 July 2006, 18:00 CDT
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that the company will hold its 2006 Research & Development Day on Tuesday, July 25, 2006 from 8:00-11:00am EST at its office in Cambridge, MA. President and CEO, Alexis Borisy, along with other members of the CombinatoRx management team, plan to provide an update on the CombinatoRx product pipeline. Interested parties may access the live webcast of the presentation by visiting the CombinatoRx website at www.combinatorx.com.
About CombinatoRx
CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease. CombinatoRx is currently developing a portfolio of six product candidates targeting multiple diseases which were discovered by applying our proprietary screening technology. For further information, please visit the CombinatoRx website at www.combinatorx.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its plans for its product candidates and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
(c) 2006 CombinatoRx, Incorporated. All rights reserved.
Source: Business Wire
Related Articles
- Circa Pictures and Production Co., Intl., Inc. (CPPD-PK) Secures Development Funding on New Film and TV Projects
- Absolute Software Identifies Top Five Computer Security Risks for Healthcare
- Devon Energy Provides Forward-Looking Estimates of Production, Reserve Additions and Capital Expenditures
- Gold River Productions, Inc. Files Inaugural Information Statement on Pinksheets.Com
- River Hawk CEO Outlines Capital Structure and Forward-Looking Plan
- CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
- Hifn Announces Full Availability and Production of High-Performance Gigabit Ethernet Security Processor
- Avicena Signs Agreement With the National Institute of Neurological Disorders and Stroke for Phase III Trial for Novel Parkinson's Disease Candidate
- HomelandSecurityStocks.Com: London Bombing Underscores Expanding Demand for Universal Guardian Secure Risks Inter-Modal Transportation Security
- Hifn(TM) Announces Production Availability, FreeBSD Support for 795x Security Processors
 |
 |
User Comments (0)
RSS Feeds